New dopamine agonist enters Parkinson disease care

The once-daily treatment selectively targets D1/D5 receptors and may be used with or without levodopa.

Category	Detail
Condition	Parkinson disease
Key Mechanisms	Dopamine agonist action to improve motor function and daily living activities.
Target Population	Adults with early Parkinson disease and those with motor fluctuations on oral levodopa.
Care Setting	Clinical trial setting for Parkinson disease management.

Tavapadon (Juvmo) approved by FDA for Parkinson disease treatment.
Improved activities of daily living at week 26 in TEMPO-1 trial.
Significant reduction in motor fluctuations in patients on oral levodopa in TEMPO-3 trial.
Most adverse events were mild or moderate.
Expected availability in the US by October 2026.

Evaluate patients with early Parkinson disease for potential treatment with dopamine agonists.

Consider tavapadon as a treatment option for patients not on oral levodopa and as an adjunct therapy.

Monitor for treatment-emergent adverse events, particularly nausea and dizziness.

Potential for mild to moderate adverse events including nausea, dizziness, and dyskinesia.

Adults with early Parkinson disease and those experiencing motor fluctuations.

Tavapadon demonstrated significant efficacy in improving daily living activities and reducing motor fluctuations.

Clinical Scorecard: New dopamine agonist enters Parkinson disease care